US FDA approves OTC Tylenol combo pill for pain relief

• The combination pill is approved for adults and children 12+ to treat headaches, back pain, muscle aches, toothaches, menstrual cramps, and minor arthritis pain
• Tylenol remains under scrutiny over alleged links to autism when used during pregnancy, with Texas suing Kenvue and a U.S. appeals court reviving related lawsuits, though no firm scientific evidence supports the connection
• Kenvue agreed to be acquired by Kimberly-Clark for over $40 billion in November, with the transaction expected to close this year

Summary: FDA Approves OTC Tylenol-Naproxen Combination Pill

The U.S. Food and Drug Administration approved a new over-the-counter combination pain relief medication on July 24, merging Kenvue's Tylenol with naproxen sodium in a single fixed-dose pill offering up to 12 hours of relief.

Key Product Details:

• Each pill contains 325 milligrams of Tylenol (acetaminophen) and 110 milligrams of naproxen sodium
• Approved for adults and children aged 12 and older
• Treats headaches, back pain, muscle aches, toothaches, menstrual cramps, and minor arthritis pain

Regulatory Context:

The FDA stated this approval aligns with the Trump administration's "Great Healthcare Plan," a federal initiative aimed at expanding access to safe pharmaceutical drugs through OTC availability.

Legal Challenges:

Tylenol faces ongoing scrutiny over alleged links between pregnancy use and autism, though no firm scientific evidence supports this connection. Texas sued Kenvue over alleged failures to warn pregnant consumers, and a U.S. appeals court recently revived lawsuits making similar claims.

Corporate Developments:

Kenvue agreed in November to be acquired by Kimberly-Clark for over $40 billion, with the transaction expected to close this year. This represents a major consolidation in the consumer healthcare sector.

Market Implications:

The new combination product could strengthen Kenvue's position in the OTC pain relief market before the Kimberly-Clark acquisition closes. However, ongoing litigation regarding Tylenol safety during pregnancy poses potential financial and reputational risks for both companies.